Small Cell Lung Cancer (SCLC)

Tarlatamab may represent a new immunotherapeutic approach for patients with small cell lung cancer, according to the investigators of the phase 2 DeLLphi-301 trial.

Developers plan to assess onvansertib plus standard of care as a frontline treatment for patients with metastatic pancreatic ductal adenocarcinoma in an investigator-initiated trial.

Data from a phase 1 trial highlight a clinically acceptable safety profile for BI 764532 in patients with extensive-stage small cell lung cancer and extrapulmonary neuroendocrine carcinomas.

Alisertib will be assessed in patients with small cell lung cancer as part of the phase 2 Study PUMA-ALI-4201.

Treatment with BI 764532 produces a manageable safety profile among those with small cell lung cancer and neuroendocrine carcinoma in a phase 1 trial.

Benmelstobart plus anlotinib and chemotherapy produce survival benefits in extensive-stage small cell lung cancer across all patient subgroups in the phase 3 ETER701 trial.

Investigators of the phase 1/2 Acclaim-3 trial will assess quaratusugene ozeplasmid in combination with atezolizumab as a treatment for those with extensive-stage small cell lung cancer.

Findings from the CROSS-FIRE study may inform individualized decision-making regarding stereotactic radiosurgery for patients with small cell lung cancer, according to Chad Rusthoven, MD.

The reduction of hematologic adverse effects with trilaciclib may improve clinical outcomes in patients with extensive-stage small cell lung cancer, according to Jerome Goldschmidt, MD.

Thoracic radiotherapy appears to be tolerable and effective in a real-world cohort of patients with extensive-stage small-cell lung cancer.

Findings from a retrospective review suggest that stereotactic radiosurgery alone may be an effective option vs whole brain radiation therapy among those with small cell lung cancer with brain metastases.

Immunogene therapy quaratusugene ozeplasmid will be evaluated in combination with atezolizumab in a phase 1/2 trial for the treatment of small cell lung cancer.

Investigators of a retrospective study suggest that reducing myelosuppression may make chemotherapy safer and reduce the need for supportive care among those with extensive-stage small cell lung cancer.

Investigators report no deaths related to treatment with ABBV-011 among patients with small cell lung cancer in a first-in-human phase 1 trial.

Patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma experience early efficacy following treatment with BI 764532.

Data from a retrospective cohort study indicate that nearly all patients receiving chemotherapy for small cell lung cancer in the community setting appear to experience myelosuppressive toxicities.

Investigators indicate that more analyses are necessary to identify patients with pretreated small cell lung cancer who will best benefit from treatment with olaparib and durvalumab.

Treatment with socazolimab plus carboplatin and etoposide appears safe in patients with small cell lung cancer, according to preliminary phase 1 study findings.

Overall survival and progression-free survival appear comparable in patients with relapsed small cell lung cancer treated with liposomal irinotecan vs topotecan.

There is a clear need for further trials and drug development to mitigate poor outcomes in patients with small cell lung cancer, according to an expert from Yale School of Medicine.

Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.

Investigators indicate that strategies are necessary to identify patients with extensive-stage small cell lung cancer who won’t benefit from immunotherapy-based treatment.

A favorable Glasgow prognostic score appears to correlate with improved overall survival and progression-free survival following treatment with atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Patients 70 years or older with limited stage small cell lung cancer appear to tolerate concurrent thoracic chemoradiotherapy and have similar disease control rates as younger patients.

Findings from the phase 1/2 CA001-030 study indicate that BMS-986012 in combination with nivolumab is well tolerated among patients with small cell lung cancer.

The FDA gave the dual epigenetic modulator JBI-802 an orphan drug designation to treat small cell lung cancer and acute myeloid leukemia.

Early results from the phase 1/2 LUPER study indicated that lurbinectedin in combination with pembrolizumab demonstrated no unexpected toxicities and promising preliminary efficacy in the second line for patients with relapsed small cell lung cancer, according to Antonio Calles, MD.

A recent study found that giving sinoatrial node radiation therapy during chemoradiotherapy may increase the likelihood of atrial fibrillation in patients with small cell lung cancer and non–small cell lung cancer.

Anne Chiang, MD, PhD, discussed results from a pilot study of biomarkers in tumors treated with ipilimumab and nivolumab in extensive-stage small cell lung cancer.

Charles M. Rudin, MD, PhD, discussed results of the phase 3 SKYSCRAPER-02 trial examining atezolizumab with carboplatin and etoposide with or without tiragolumab in untreated extensive-stage small cell lung cancer.